Literature DB >> 3028777

Both Epstein-Barr virus (EBV)-encoded trans-acting factors, EB1 and EB2, are required to activate transcription from an EBV early promoter.

A Chevallier-Greco, E Manet, P Chavrier, C Mosnier, J Daillie, A Sergeant.   

Abstract

We have identified two Epstein--Barr virus (EBV) transacting factors which are involved in the transcriptional activation of EBV early promoters in latently infected Raji cells. In Raji cells, expression of the factor EB1 encoded by the open reading frame (ORF) BZLF1 is necessary and sufficient to disrupt latency. However, factor EB2 encoded by the ORF BMLF1- BSLF2 does not disrupt latency when expressed alone in Raji cells. Expression of an EBV activatable early promoter depends on the presence of both EB1 and EB2.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3028777      PMCID： PMC1167318          DOI： 10.1002/j.1460-2075.1986.tb04635.x

Source DB:  PubMed          Journal:  EMBO J        ISSN： 0261-4189            Impact factor:   11.598


  50 in total

1.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

2.  Epstein-Barr virus with heterogeneous DNA disrupts latency.

Authors:  G Miller; M Rabson; L Heston
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

3.  Two Epstein-Barr viral nuclear neoantigens distinguished by gene transfer, serology, and chromosome binding.

Authors:  E A Grogan; W P Summers; S Dowling; D Shedd; L Gradoville; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

4.  Activation of the SV40 late promoter: direct effects of T antigen in the absence of viral DNA replication.

Authors:  J M Keller; J C Alwine
Journal:  Cell       Date:  1984-02       Impact factor: 41.582

5.  Specific interaction between enhancer-containing molecules and cellular components.

Authors:  H R Schöler; P Gruss
Journal:  Cell       Date:  1984-02       Impact factor: 41.582

6.  Structure of defective DNA molecules in Epstein-Barr virus preparations from P3HR-1 cells.

Authors:  M S Cho; G W Bornkamm; H zur Hausen
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

7.  Identification of Epstein-Barr nuclear antigen polypeptide in mouse and monkey cells after gene transfer with a cloned 2.9-kilobase-pair subfragment of the genome.

Authors:  D K Fischer; M F Robert; D Shedd; W P Summers; J E Robinson; J Wolak; J E Stefano; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

8.  A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates.

Authors:  A Polack; G Hartl; U Zimber; U K Freese; G Laux; K Takaki; B Hohn; L Gissmann; G W Bornkamm
Journal:  Gene       Date:  1984-03       Impact factor: 3.688

9.  Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein.

Authors:  S Fennewald; V van Santen; E Kieff
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

10.  Stimulation of simian virus 40 late gene expression by simian virus 40 tumor antigen.

Authors:  J Brady; J B Bolen; M Radonovich; N Salzman; G Khoury
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205
View more
  220 in total

1.  Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.

Authors:  R J Kraus; S J Mirocha; H M Stephany; J R Puchalski; J E Mertz
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Possible involvement of IL-12 expression by Epstein-Barr virus in Sjögren syndrome.

Authors:  M Horiuchi; S Yamano; H Inoue; J Ishii; Y Nagata; H Adachi; M Ono; J N Renard; F Mizuno; Y Hayashi; I Saito
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

3.  The C-terminal region but not the Arg-X-Pro repeat of Epstein-Barr virus protein EB2 is required for its effect on RNA splicing and transport.

Authors:  M Buisson; F Hans; I Kusters; N Duran; A Sergeant
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  The amino-terminal C/H1 domain of CREB binding protein mediates zta transcriptional activation of latent Epstein-Barr virus.

Authors:  D Zerby; C J Chen; E Poon; D Lee; R Shiekhattar; P M Lieberman
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

Review 5.  The genetic approach to the Epstein-Barr virus: from basic virology to gene therapy.

Authors:  H J Delecluse; W Hammerschmidt
Journal:  Mol Pathol       Date:  2000-10

6.  Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation.

Authors:  C D Darr; A Mauser; S Kenney
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  Epstein-Barr virus SM protein interacts with mRNA in vivo and mediates a gene-specific increase in cytoplasmic mRNA.

Authors:  V Ruvolo; A K Gupta; S Swaminathan
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  The Epstein-Barr virus SM protein induces STAT1 and interferon-stimulated gene expression.

Authors:  Vivian Ruvolo; Lorena Navarro; Clare E Sample; Michael David; Seung Sung; Sankar Swaminathan
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

9.  The CBP bromodomain and nucleosome targeting are required for Zta-directed nucleosome acetylation and transcription activation.

Authors:  Zhong Deng; Chi-Ju Chen; Michaela Chamberlin; Fang Lu; Gerd A Blobel; David Speicher; Lisa Ann Cirillo; Kenneth S Zaret; Paul M Lieberman
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

10.  Role of CCAAT/enhancer-binding protein alpha (C/EBPalpha) in activation of the Kaposi's sarcoma-associated herpesvirus (KSHV) lytic-cycle replication-associated protein (RAP) promoter in cooperation with the KSHV replication and transcription activator (RTA) and RAP.

Authors:  Shizhen Emily Wang; Frederick Y Wu; Masahiro Fujimuro; Jianchao Zong; S Diane Hayward; Gary S Hayward
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.